From Arrowhead Pharmaceuticals PASADENA, Calif.–(BUSINESS WIRE)–Jul. 17, 2023– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2 clinical trial… Read More »
Arrowhead files for regulatory clearance to start a Phase 1/2 study in FSHD
Passion and hope at the IRC
The immeasurable value of face to face meetings by Raj Badiani, FSHD UK I was given the opportunity to attend the FSHD Society’s International Research Congress (IRC) in Milan this… Read More »
Advocacy and industry partners launch new global coalition to speed delivery of new therapies for FSHD
Project Mercury unites patients, industry, research and clinical communities in groundbreaking initiative from Fulcrum Therapeutics Today on World FSHD Day, the FSHD Society and Fulcrum Therapeutics announce the launch of… Read More »
Kate Therapeutics is pursuing FSHD treatment
The company’s MyoAAV promises a less toxic way to deliver gene therapies by June Kinoshita, Senior Director of Research and Education Kate Therapeutics, Inc. (KateTx), a San Diego-based biopharma company,… Read More »
Unleashing the Power of Collaboration: Achieving More for FSHD Together
by Ken Kahtava, FSHD Society This blog post was originally published here on the Project Mercury website. On 11 May in Leiden, NL, the Project Mercury global task force members met for… Read More »